Covestor’s Praxis Precision Medicines PRAX Stock Holding History

Covestor’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8K	Sell	23 -1	-4%	-$317	﹤0.01%	1741
2026 Q1	$8K	Buy	24 +22	+1,100%	+$6.81K	0.01%	1591
2025 Q4	$1K	Hold	2	–	–	﹤0.01%	2144
2025 Q3	$0	Hold	2	–	–	﹤0.01%	2655
2025 Q2	$0	Buy	2 +1	+100%	+$38	﹤0.01%	2634
2025 Q1	$0	Hold	1	–	–	﹤0.01%	2614
2024 Q4	$0	Buy	+1	New	+$72	﹤0.01%	2623

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Covestor's PRAX Position: Q2 2026 in Review

Covestor reduced its Praxis Precision Medicines (PRAX) stake by 4.2% in Q2 2026, selling an estimated $317 and leaving 23 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1741.

Covestor first reported a position in PRAX in Q4 2024 and has held it in 7 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Covestor held 23 shares of Praxis Precision Medicines worth $8K as of Q2 2026.
Covestor sold 1 Praxis Precision Medicines share in Q2 2026, an estimated $317.
Praxis Precision Medicines made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #1741 holding.
Covestor first reported a position in Praxis Precision Medicines in Q4 2024 and has held it in 7 quarters since.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.